Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Paragon 28 Inc (NY: FNA )

6.680 +0.240 (+3.73%)
Streaming Delayed Price Updated: 10:26 AM EDT, Sep 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Paragon 28 Inc

< Previous 1 2 3 4 Next >
Paragon 28 Reports Fourth Quarter and Full Year 2022 Financial Results and Provides 2023 Financial Guidance
From Paragon 28, Inc.
Via Business Wire
Paragon 28 to Present at Upcoming Investor Conferences
From Paragon 28, Inc.
Via Business Wire
Paragon 28, Inc. Announces Closing of Underwriters’ Option to Purchase Additional Shares in Connection with Public Offering of Common Stock
From Paragon 28, Inc.
Via Business Wire
Paragon 28 To Report Fourth Quarter and Full Year 2022 Financial Results on March 2, 2023
From Paragon 28, Inc.
Via Business Wire
Paragon 28, Inc. Announces Pricing of Public Offering
From Paragon 28, Inc.
Via Business Wire
Paragon 28, Inc. Announces Proposed Public Offering of Common Stock
From Paragon 28, Inc.
Via Business Wire
Paragon 28 Announces Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2022
From Paragon 28, Inc.
Via Business Wire
Paragon 28 to Present at The 34th Annual Piper Sandler Healthcare Conference
From Paragon 28, Inc.
Via Business Wire
Paragon 28 Reports Third Quarter 2022 Financial Results and Increases 2022 Net Revenue Guidance
From Paragon 28, Inc.
Via Business Wire
Paragon 28 To Report Third Quarter 2022 Financial Results on November 10, 2022
From Paragon 28, Inc.
Via Business Wire
Paragon 28 to Present at The Morgan Stanley 20th Annual Global Healthcare Conference
From Paragon 28, Inc.
Via Business Wire
Paragon 28 Announces Changes to its Board of Directors
From Paragon 28, Inc.
Via Business Wire
Paragon 28 Reports Second Quarter 2022 Financial Results and Increases 2022 Net Revenue Guidance
From Paragon 28, Inc.
Via Business Wire
Paragon 28 To Report Second Quarter 2022 Financial Results on August 3, 2022
From Paragon 28, Inc.
Via Business Wire
Paragon 28 to Present at The Canaccord Genuity 42nd Annual Growth Conference
From Paragon 28, Inc.
Via Business Wire
Paragon 28 Launches Mobile Medical Education Lab Tour, Expanding Opportunities for Foot and Ankle Surgeon Education
From Paragon 28, Inc.
Via Business Wire
Paragon 28 Launches Monkey Rings™ Circular External Fixation System
From Paragon 28, Inc
Via Business Wire
Paragon 28 Launches TenoTac™ 2.0 Soft Tissue Stabilization System for Hammertoe and Soft Tissue Repair
From Paragon 28, Inc.
Via Business Wire
Paragon 28 Expands Soft Tissue Portfolio with Grappler™ Suture Anchor System Launch
From Paragon 28, Inc.
Via Business Wire
Paragon 28 Reports First Quarter 2022 Financial Results and Increases 2022 Net Revenue Guidance
From Paragon 28, Inc.
Via Business Wire
Paragon 28 Launches Paratrooper™ Plantar Plate System for Hammertoe and Soft Tissue Repair
From Paragon 28, Inc.
Via Business Wire
Paragon 28 Launches R3ACT™ Stabilization System for Ankle Injuries
From Paragon 28, Inc.
Via Business Wire
Paragon 28 To Report First Quarter 2022 Financial Results on May 9, 2022, and Present at the 2022 Bank of America Healthcare Conference on May 10, 2022
From Paragon 28, Inc.
Via Business Wire
Paragon 28 Announces Appointment of Meghan Scanlon to Board of Directors
From Paragon 28, Inc.
Via Business Wire
Paragon 28 to Report Fourth Quarter and Full Year 2021 Financial Results on March 8, 2022
From Paragon 28, Inc.
Via Business Wire
Paragon 28 Announces Acquisition of Disior
From Paragon 28, Inc.
Via Business Wire
Paragon 28 Announces Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2021
From Paragon 28, Inc.
Via Business Wire
Paragon 28, Inc. R3ACT™ Stabilization System Cleared by FDA
From Paragon 28, Inc.
Via Business Wire
Paragon 28 to Present at 24th Annual Needham Growth Conference
From Paragon 28, Inc.
Via Business Wire
Paragon 28’s Patient Specific Titanium Talus Spacer Has Been Approved by the U.S. Food and Drug Administration
From Paragon 28, Inc.
Via Business Wire
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.